Not yet recruiting, this trial assesses a repeated low level red light therapy device for dry age related macular degeneration and highlights regulatory considerations for device based therapy.
Dry age related macular degeneration is a leading cause of vision loss among older adults. The registry outlines a device driven approach intended to deliver light therapy in repeated sessions with a sham control in the comparator arm.
The sponsor listed for this study is The Hong Kong Polytechnic University, indicating strong academic leadership in evaluating a novel therapy approach for AMD using a medical device. The clinical trials record notes two interventions: the RLRL device and a sham device.
The trial status is not yet recruiting, meaning patient enrollment has not begun at the time of the posting. Researchers and regulators will watch for safety and performance signals related to device use in the target population.
What is the trial about
The study evaluates a device that delivers repeated low level red light to the retina in dry age related macular degeneration. As a registry entry, it provides information on intended purpose and study design without claiming efficacy at this stage.
By documenting the device type and comparator, the record helps regulators and stakeholders understand how this therapy could fit into future guidelines for device based interventions in ocular diseases.
How is the trial designed
The record lists two interventions: the RLRL device and a sham device. The design details such as randomization and endpoints are not elaborated in the current posting, but the inclusion of a sham comparator supports a controlled assessment of device effect versus placebo.
Which device is studied and what safety considerations apply
The investigational device is referred to as the repeated low level red light device, abbreviated RLRL. Sponsor attribution to The Hong Kong Polytechnic University indicates established oversight. The status not yet recruiting implies that safety evaluations will occur as the trial progresses and will be reported in future updates.
What are the regulatory implications for device based therapy
From a regulatory perspective the record documents the intended purpose and the safety oriented design of the RLRL device. Regulators may monitor the trial as part of ongoing oversight of device based therapies for ocular conditions, particularly when human subjects are involved and a sham control is used to assess effect.
What this means for patients and clinicians
For patients living with dry age related macular degeneration this trial represents an early stage step in evaluating a device based therapy. Clinicians should monitor the public record to understand when results become available and how they may influence future treatment options. The not yet recruiting status means enrollment is unlikely until later stages.
1. What is the aim of the trial?
The aim is to evaluate a repeated low level red light therapy device for dry age related macular degeneration and to compare it with a sham control as described in the registry.
2. What interventions are used?
The interventions listed are the RLRL device and a sham device.
3. Who sponsors the study?
The Hong Kong Polytechnic University is listed as the sponsor.
4. What is the trial status?
The record shows not yet recruiting at this time.
Overall the study emphasizes a device based approach for dry age related macular degeneration and regulatory observers will watch for enrollment progress and eventual results. Readers should prepare for updates that may influence future device governance and patient care.
This information is intended for professionals. It does not constitute legal advice. Always consult current regulatory guidelines for medical device trials and approvals.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07409389?term=medical+device